Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Larry Maxwell

Showing results (21-30 of 158) with videos related to

Pageof 16
Sort By:
Obstetrics and Gynecology|January 9, 2003
Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compressionDaniel L Clarke-Pearson, Richard K Dodge, Ingrid Synan, et al.
Journal of Cancer|January 8, 2014
Current approaches and challenges in managing and monitoring treatment response in ovarian cancerCharlotte S Marcus, G Larry Maxwell, Kathleen M Darcy, et al.
Molecules (Basel, Switzerland)|October 19, 2019
Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1ASana Waheed, Robert Ys Cheng, Yovanni Casablanca, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 11, 2008
Infant feeding and the incidence of endometrial cancerFei Xue, Leena A Hilakivi-Clarke, G Larry Maxwell, et al.
Molecules (Basel, Switzerland)|November 11, 2025
RETRACTED: Waheed et al. Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A. <i>Molecules</i> 2019, <i>24</i>, 3722Sana Waheed, Robert Ys Cheng, Yovanni Casablanca, et al.
Oncotarget|January 27, 2018
Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMPSana Waheed, Batsukh Dorjbal, Chad A Hamilton, et al.
Obstetrics and Gynecology|October 18, 2002
Surgical staging in patients with ovarian tumors of low malignant potentialWilliam E Winter, Paul R Kucera, William Rodgers, et al.
Obstetrics and Gynecology|October 18, 2002
Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiariesG Larry Maxwell, Jay W Carlson, Mark Ochoa, et al.
Cancer Biomarkers : Section a of Disease Markers|December 29, 2006
Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instabilityJohn I Risinger, G V R Chandramouli, G Larry Maxwell, et al.
Biomedicines|July 2, 2025
RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. <i>Biomedicines</i> 2020, <i>8</i>, 73Ana Paucarmayta, Hannah Taitz, Latoya McGlorthan, et al.
Pageof 16

Showing results (21-30 of 158) with videos related to

Sort By:
Pageof 16
Obstetrics and Gynecology|January 9, 2003
Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compressionDaniel L Clarke-Pearson, Richard K Dodge, Ingrid Synan, et al.
Journal of Cancer|January 8, 2014
Current approaches and challenges in managing and monitoring treatment response in ovarian cancerCharlotte S Marcus, G Larry Maxwell, Kathleen M Darcy, et al.
Molecules (Basel, Switzerland)|October 19, 2019
Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1ASana Waheed, Robert Ys Cheng, Yovanni Casablanca, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 11, 2008
Infant feeding and the incidence of endometrial cancerFei Xue, Leena A Hilakivi-Clarke, G Larry Maxwell, et al.
Molecules (Basel, Switzerland)|November 11, 2025
RETRACTED: Waheed et al. Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A. <i>Molecules</i> 2019, <i>24</i>, 3722Sana Waheed, Robert Ys Cheng, Yovanni Casablanca, et al.
Oncotarget|January 27, 2018
Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMPSana Waheed, Batsukh Dorjbal, Chad A Hamilton, et al.
Obstetrics and Gynecology|October 18, 2002
Surgical staging in patients with ovarian tumors of low malignant potentialWilliam E Winter, Paul R Kucera, William Rodgers, et al.
Obstetrics and Gynecology|October 18, 2002
Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiariesG Larry Maxwell, Jay W Carlson, Mark Ochoa, et al.
Cancer Biomarkers : Section a of Disease Markers|December 29, 2006
Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instabilityJohn I Risinger, G V R Chandramouli, G Larry Maxwell, et al.
Biomedicines|July 2, 2025
RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. <i>Biomedicines</i> 2020, <i>8</i>, 73Ana Paucarmayta, Hannah Taitz, Latoya McGlorthan, et al.
Pageof 16